Posted by Michael Wonder on 04 Jan 2026
GC Biopharma’s Livmarli listed for national health insurance coverage for Alagille syndrome
2 January 2026 - GC Biopharma said Livmarli (maralixibat chloride), a treatment for Alagille syndrome, has been officially listed on the health insurance benefit list following a notice from the Ministry of Health and Welfare.
The coverage took effect on Thursday, making the drug the first health insurance-covered treatment option for the Alagille syndrome indication in Korea.
